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OBJECTIVES We sought to evaluate hypoestrogenemia of hypothalamic origin and its association with
angiographic coronary artery disease (CAD) in premenopausal women.
BACKGROUND Coronary artery disease in premenopausal women appears to have a particularly poor
prognosis. Primate animal data suggest that premenopausal CAD is strongly determined by
psychosocial stress-induced central disruption of ovulatory cycling and resulting hypoestrogenemia.
METHODS We assessed reproductive hormone blood levels and angiographic CAD using core labora-
tories in 95 premenopausal women with coronary risk factors who were enrolled in the
National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Eval-
uation and were undergoing coronary angiography for evaluation for suspected ischemia.
RESULTS Premenopausal women with angiographic CAD (n  13) had significantly lower estradiol,
bioavailable estradiol, and follicle-stimulating hormone (FSH) (all p  0.05) than women
without angiographic CAD (n  82), even after controlling for age. Hypoestrogenemia of
hypothalamic origin, defined as estradiol 184 pmol/l (50 pg/ml), FSH 10 IU/l, and
luteinizing hormone 10 IU/l, was significantly more prevalent among the women with
CAD than those without CAD (9/13 [69%] vs. 24/82 [29%], respectively, p  0.01).
Hypoestrogenemia of hypothalamic origin was the most powerful predictor of angiographic
CAD in a multivariate model (odds ratio [OR] 7.4 [confidence interval (CI) 1.7 to 33.3], p
0.008). Anxiolytic/sedative/hypnotic and antidepressant medication use were independent
predictors of hypoestrogenemia of hypothalamic origin in a multivariate model (OR 4.6 [CI
1.3 to 15.7], p  0.02, OR 0.10 [CI 0.01 to 0.92], p  0.04, respectively).
CONCLUSIONS Among premenopausal women undergoing coronary angiography for suspected myocardial
ischemia, disruption of ovulatory cycling characterized by hypoestrogenemia of hypothalamic
origin appears to be associated with angiographic CAD. (J Am Coll Cardiol 2003;41:
413–9) © 2003 by the American College of Cardiology Foundation
It has only recently been realized that the higher gender-
specific coronary mortality observed in women (1–3) is due
to increased death rates among relatively young women.
Specifically, Vaccarino et al. (4) demonstrated that among
women under 50 years of age, the hospital mortality rate for
myocardial infarction was more than twice that for age-
matched men (6.1% vs. 2.9%, p  0.001 for interaction
between age and gender). Little is known regarding rela-
tively young, premenopausal women and coronary artery
disease (CAD) pathophysiology and management. Because
much CAD prevalence is attributable to older, postmeno-
pausal women (5,6), recent interest has focused on increased
rates of coronary angiography in older women (7) as well as
hormone replacement therapy in postmenopausal women
(8–10). Evaluation of CAD in premenopausal women has
been overlooked, despite its being the leading killer of
women in this age group, outpacing even breast cancer (4).
Previous work in primates has suggested that premeno-
pausal atherosclerosis is related to stress-induced central
disruption of ovulatory cycling and resulting hypoestrogen-
emia. Specifically, atherosclerosis is enhanced in young
female cynomolgus monkeys subjected to psychosocial stress
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and subordinate social status that result in hypoestrogen-
emia of hypothalamic origin (11–13). Accordingly, we
tested the hypothesis that hypoestrogenemia of hypotha-
lamic origin is associated with CAD in young women in the
Women’s Ischemia Syndrome Evaluation (WISE).
METHODS
The WISE study is a National Heart, Lung, and Blood
Institute (NHLBI)–sponsored four-center investigation de-
signed to improve diagnostic testing and advance new
hypotheses relative to the pathophysiology of ischemic heart
disease in women. Women undergoing clinically ordered
coronary angiography for suspected ischemia, but without
unstable myocardial ischemia, were recruited into WISE.
Subjects underwent a physical examination that included
heart rate, blood pressure, height, weight, body mass index,
and waist-hip ratio determination; demographics; medical
history; and quantitative coronary angiography. Coronary
risk factors were defined according to the National Choles-
terol Education Program, Adult Panel III (14). The com-
plete design and methodology of the WISE study are
described elsewhere (15).
Premenopausal status and menstrual phase status deter-
mination. Premenopausal status and menstrual phase (fol-
licular, luteal, menstrual, anovulatory) were determined
using a previously published reproductive status algorithm
developed for the WISE (15). Premenopausal status was
defined as no current use of hormone or oral contraceptive
therapy, age55 years, follicle-stimulating hormone (FSH)
15 IU/l and luteinizing hormone (LH)  FSH, and no
history of bilateral oophorectomy. Current menstrual cy-
cling was not considered a determinative variable in the
algorithm, because 13/95 (14%) of the premenopausal
women had a prior hysterectomy and because we hypothe-
sized that women with the full syndrome of hypoestrogen-
emia of hypothalamic origin would have functional hypo-
thalamic amenorrhea. Perimenopausal women, defined as
FSH 15–30 IU/l and FSH  LH, were not included in the
premenopausal group. All determinations were blind to the
coronary angiography.
Environmental stress, psychological, and social status
assessment. Chronic (preceding five years) environmental
stress was sampled by a single question at study entry using
a five-point scale questionnaire previously demonstrated to
be predictive of future adverse cardiac events in patients
with CAD (16). A score of 4 indicates chronically
elevated environmental stress. Additional psychological as-
sessments evaluated in the current report included typical
depression (17) and trait anxiety (18). A score of16 on the
Beck Depression scale was considered to be depressive
symptoms, and a score 19 on the Spielberger trait anxiety
scale was considered to be anxious. Current use of psycho-
tropic medication was considered evidence of more chronic
psychological distress. Socioeconomic status assessment in-
cluded marital/partner status, years of education, and job
situation.
Reproductive hormone and lipoprotein core laborato-
ries. Reproductive hormone assays (estradiol, bioavailable
estradiol, estrone, progesterone, FSH, LH) were performed
at the WISE reproductive hormone core laboratory from
stored serum samples by an experienced technician (19).
Validated steroid and protein assay methods were used,
samples were assayed in batches of 100, and each determi-
nation was measured in duplicate. Methodology was main-
tained for the duration of the study. Previous work from this
laboratory has demonstrated within- and between-assay
coefficients of variation, respectively, of 15% and 16% for
estrone, 8% and 12% for estradiol, and 3.7% and 4.2% for
bioavailable estradiol (20). For the purpose of these analyses,
“hypothalamic hypoestrogenemia” was defined as blood
estradiol level 184 pmol/l (50 pg/ml), FSH level 10
IU/l, and LH level 10 IU/l. This definition was prospec-
tively derived from examination of hypothalamic hypo-
estrogenemia primate animal (12,13) and human data (21).
Lipoprotein determinations were performed at a lipid
core laboratory enrolled in the Centers for Disease Control
and Prevention lipid standardization program previously
used in multiple NHLBI-sponsored lipid-lowering inter-
vention trials using the Friedewald formula, as previously
published (22). The coefficients of variation for total cho-
lesterol, high-density lipoprotein cholesterol, and hypoestro-
genemia were 1.80%, 1.23%, and 3.93%, respectively.
Measurement of coronary angiography. An experienced
core laboratory assessed coronary angiography. Measure-
ments included quantitative assessment of the presence,
severity, and complexity of epicardial coronary artery steno-
sis, using previously published methods, and a coronary
severity score (23). For these analyses, angiographic CAD
was defined as 70% luminal diameter stenosis in at least
one epicardial coronary artery. Analyses using an alternative
definition for CAD of50% luminal diameter stenosis in at
least one epicardial coronary artery provided similar results
and are not presented.
Statistical analysis. Comparisons between women with
and without angiographic CAD were performed by the
Wilcoxon rank-sum test for continuous measures and by the
Fisher exact test for discrete measures. Spearman correla-
tions were performed between reproductive hormone levels
and the coronary severity score. A p value of 0.05 was
considered statistically significant. Stepwise logistic regres-
sion analysis was used to model angiographic CAD as a
function of hypoestrogenemia of hypothalamic origin and
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other coronary risk factors, and to model hypoestrogenemia
of hypothalamic origin as a function of psychosocial and
other factors. Summary statistics for the regression models
included the c-statistic (a measure of association of pre-
dicted probabilities and observed prevalence of a binary
outcome) and R2 (rescaled for use in logistic regression). All
analyses were performed using the SAS 6.12 software.
RESULTS
Among the 855 WISE participants with complete demo-
graphic, reproductive status, and coronary angiographic
data, 95 (11%) were premenopausal, denied use of hormone
therapy or oral contraceptives, and had no prior diagnosis of
CAD (Table 1). Notably, despite a high prevalence of
coronary risk factors, only a minority (14%) of these
premenopausal women had angiographic CAD.
Coronary risk factor assessment among the women with
(n  13) and without (n  82) angiographic CAD (Table
1) demonstrated a higher prevalence of diabetes mellitus (p
 0.02) and a higher waist-hip ratio (p 0.01) in the CAD
group. The global adenosine triphosphate (ATP) III coro-
nary event risk calculation (13) was significantly higher in
the CAD group (p  0.05). Assessment of chronic comor-
bid conditions was similar between the groups, although
aspirin use was higher (p  0.004) and there was a trend
toward greater corticosteroid drug use among the women
with CAD (p  0.09) (Table 1).
There were no group differences in historical reproductive
variables, and current menstrual cycle phase was similarly
distributed between the two groups (Table 2). Notably,
among the 33 women with hypoestrogenemia of hypotha-
lamic origin, 20 (61%) were categorized as anovulatory
during the current cycle. There were no differences between
the women with and without CAD with regard to reported
environmental stress, depression, anxiety, psychotropic
medication use, anorexia/bulimia, weight cycling, or socio-
economic status, indicated by marital status, education, and
job situation/category (data not shown).
Comparison of reproductive hormone levels by angio-
graphic CAD status is shown in Figure 1. The women with
angiographic CAD had significantly lower estradiol, bio-
Table 1. Premenopausal WISE Women Demographic and Coronary Risk Factor Variables
Variable
Overall
(n  95)
No CAD
(n  82)
CAD
(n  13) p*
Age/yrs, mean (SD) 43 (6) 43 (6) 44 (6) 0.54
Median (range) 43 (21–54) 43 (21–54) 44 (35–54)
Race (% white) 74 73 77  0.99
Current smoking (%) 24 24 23  0.99
Hx DM (%) 20 16 46 0.02
Hx of HTN (%) 48 49 46 0.86
Hx of HYPERLIP (%) 28 28 30  0.99
FHx of premCAD (%) 76 77 67 0.48
BMI, mean (SD) 31.2 (6.9) 31.5 (7.2) 28.9 (4.4) 0.21
Median (range) 30.8 (17.7–52.2) 31.1 (17.7–52.2) 28.6 (22.2–36.1)
WHR, mean (SD) 0.84 (0.08) 0.83 (0.07) 0.90 (0.08) 0.01
Median (range) 0.85 (0.70–1.06) 0.84 (0.70–1.06) 0.89 (0.77–1.05)
ATP-III 10-year 7 5 23 0.05
Coronary risk 3% (%)*
Corticosteroid use (%) 4 2 15 0.09
Aspirin use (%) 38 32 77 0.004
Coronary disease (SD) 10.0 (12.1) 6.0 (2.2) 34.6 (18.6) 0.0001
Severity score
Median (range) 5.0 (5–78.2) 5.0 (5–14.5) 26.5 (14.0–78.2)
Typical angina (%) 38 35 62 0.24
*p compares No CAD to CAD women, using Wilcoxon Rank Test for continuous variables and 2-tailed Fisher’s Exact test for percentages.
ATP-III  National Cholesterol Education Program, Adult Treatment Panel-III; BMI  body mass index; CAD  angiographic coronary artery disease defined as 70%
luminal diameter stenosis in 1 epicardial coronary artery; DM  diabetes mellitus; HTN  hypertension; Hx  history; HYPERLIP  hyperlipidemia; F  family; Prem
 premature; WHR  waist-hip ratio; WISE  Women’s Ischemia Syndrome Evaluation.
Table 2. Premenopausal WISE Women Historical
Reproductive Variables
Variable
No
CAD
(n  82)
CAD
(n  13) p*
History of irregular menstrual
periods (%)
18 8 0.69
Current menstrual phase (%)
Follicular 33 8 0.10
Luteal 32 38 0.75
Menstrual 17 15  0.99
Anovulatory 18 38 0.14
History of hysterectomy (%) 20 8 0.45
History of PCO (%) 6 0  0.99
No. times pregnant, Mean (SD) 3.3 (1.5) 2.6 (1.3) 0.14
Median (range) 3 (1–10) 2.5 (1–5)
No. live births, Mean (SD) 2.8 (1.2) 2.2 (1.0) 0.11
Median (range) 3 (0–6) 2 (1–4)
Hypothalamic hypoestrogenemia (%) 29 69 0.01
*p values based on Wilcoxon rank test for continuous variables and 2-tailed Fisher
exact test for percentages.
CAD  angiographic coronary artery disease defined as 70% luminal diameter
stenosis in 1 epicardial coronary artery; NA  not available; PCO  polycystic
ovary disease; WISE  Women’s Ischemia Syndrome Evaluation.
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available estradiol, estrone, and FSH levels than the women
without angiographic CAD. Correlation analyses demon-
strated moderate correlations between the coronary severity
score and estradiol (r  0.18, p  0.08) and bioavailable
estradiol (r0.19, p 0.06). Overall, 33/95 (35%) of the
women had hypoestrogenemia of hypothalamic origin, and
women with angiographic coronary disease had a signifi-
cantly higher prevalence of this than women without CAD
(9/13 [69%] vs. 24/82 [29%], p  0.01) (Table 2). Women
with hypothalamic hypoestrogenemia also had a higher
mean coronary artery severity score (13.8  14.6 vs. 7.9 
10.0, p  0.005, respectively) than women without hypo-
thalamic hypoestrogenemia.
We next evaluated whether hypoestrogenemia of hypo-
thalamic origin, and hypoestrogenemia alone (estradiol
184 pmol/l [50 pg/ml]), independently contributed to the
presence of angiographic CAD. Correlations and partial
correlations among estradiol, LH, and FSH demonstrated
that they were highly related (r values above 0.5, p values
0.001). In a multivariate model, we initially evaluated
demographics, risk factors, blood lipoprotein levels, psycho-
logic scores, and medication usage (Table 3). The presence
of hypothalamic hypoestrogenemia, aspirin use, and ATP-
III 10-year risk 3% were the only remaining significant
predictors after reducing the model through stepwise logis-
tic regression. In a separate model, hypoestrogenemia alone
was also a significant independent predictor. Although the
specificity of prediction with hypoestrogenemia alone was
lower than that with hypoestrogenemia of hypothalamic
origin (67% vs. 71%, respectively), this difference was not
significant. In separate models without the hypoestrogen-
emia variable, aspirin use and the ATP III global coronary
risk score were the only remaining significant predictors,
with diabetes entering as a potentially significant variable (p
 0.07).
We evaluated whether higher rates of recent illness or
hospitalization leading to the index coronary angiography in
women in our study with CAD could have a potential
confounding effect of acutely lowering blood reproductive
hormone levels (24). We assessed recent acute illness,
defined as unstable angina in the past six weeks, renal
dysfunction, asthma, or current antibiotic use, by angio-
graphic CAD status and found no group differences in any
of the medical comorbidity variables.
Finally, we explored potential biobehavioral associations
between the psychosocial variables and hypoestrogenemia of
hypothalamic origin as a possible mechanistic link to CAD.
Angiographic CAD was significantly more prevalent in the
women with than those without hypoestrogenemia of hy-
pothalamic origin (9/33 [27%] vs. 4/62 [6%], p  0.01).
Coronary risk factors, ATP III coronary risk, historical
reproductive variables, and psychological and social variables
Figure 1. Reproductive hormone levels stratified by angiographic coronary artery disease (CAD) (70% luminal diameter stenosis in at least one epicardial
coronary artery) (n  95 women) (to convert bioavailable estradiol, estradiol, and estrone from picograms per milliliter to picomoles per liter, divide
picomoles per liter by 3.671). The bottom and top of the boxes represent the 25th and 75th percentiles, respectively. The center horizontal line gives
the sample median. The central vertical lines (the whiskers) range from the box to the 1.5 interquartile ranges from each side of the box (where an
interquartile range is the distance between the 25th and the 75th percentile).
Table 3. Significant Predictors of Coronary Artery Disease*
Final Logistic Regression Model
OR Conf. Intervals p
Hypoestrogenemia 7.4 1.7–33.3 0.008
Aspirin use last week 7.6 1.7–33.7 0.008
ATP-III 10-year risk 3%** 8.3 1.2–59.6 0.04
c-Statistic  0.86
R2  0.36
*Coronary artery disease defined as 70% luminal diameter stenosis in one
epicardial coronary artery. **From reference (14). The variables of age, race, hyper-
tension, diabetes mellitus, body mass index, waist-hip ratio, current smoking, family
history of premature coronary artery disease, blood lipoprotein levels, Beck depression,
environmental stress, typical angina, aspirin use, and psychotropic medication use
were evaluated in the multivariate model.
ATP-III  National Cholesterol Education Program, Adult Treatment Panel-III.
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did not differ between women with and without hypoestro-
genemia of hypothalamic origin (data not shown), although
there was a trend toward more diabetes mellitus among the
women with hypoestrogenemia of hypothalamic origin
(10/33 [30%] vs. 9/61 [15%], p  0.07, respectively).
Notably, women with hypoestrogenemia of hypothalamic
origin took less antidepressant medication (1/33 [3%] vs.
11/62 [18%], p 0.05) but had a trend toward taking more
antianxiety/sedative/hypnotic medication (9/33 [27%] vs.
9/62 [14%], p  0.13) than the other group. In regression
models with and without CAD as a predictor of hypoestro-
genemia of hypothalamic origin, anxiolytic/sedative/
hypnotic medication use, absence of antidepressant use, and
diabetes mellitus were significant independent predictors
(Table 4).
DISCUSSION
Our findings demonstrate, for the first time, that hypoestro-
genemia of hypothalamic origin is associated with CAD in
premenopausal women undergoing coronary angiography
for suspected myocardial ischemia. These results support the
concept that female protection is lost when ovarian function
is disrupted. Notably, traditional coronary risk factors, with
the exception of diabetes, were similarly prevalent in women
with and without CAD, suggesting that hypothalamic
hypoestrogenemia may be a particularly potent risk factor
for premenopausal women. These results are consistent with
previous primate work demonstrating that atherosclerosis is
significantly accelerated in monkeys with hypoestrogenemia
secondary to disrupted ovarian function of hypothalamic
origin induced by stress due to social subordination (11–13),
as well as with work in humans demonstrating elevated
CAD risk associated with premature menopause in women
(25–27).
The current study results also provide a potential mech-
anism to explain the greater CAD mortality experienced in
relatively younger women when compared with age-
matched men with CAD (10). In this study, neither CAD
severity nor medical treatment regimens could account for
the increased mortality observed in these younger women,
suggesting the possibility of inherent gender-specific patho-
physiologic differences. Previous animal (28) and human
work (4,29) has demonstrated that hypoestrogenemia in
females is accompanied by coronary artery dysfunction,
characterized by a diminution of normal vasodilation and
even vasoconstriction in response to a stressor. Our current
results document that premenopausal women with CAD
may have hypoestrogenemia and, therefore, may have more
adverse coronary arterial dysfunction. Although we are
unable to link these results with mortality in this relatively
small sample size, they suggest that premenopausal women
with CAD could be at higher mortality risk stemming from
hypoestrogenemia-related adverse physiologic effects.
Previous animal (11–13) and human investigation
(21,30,31) document an association between environmental
psychologic stress and functional hypothalamic amenorrhea,
which was present in our study in 61% of the women with
hypoestrogenemia of hypothalamic origin and probably
represents the full syndrome of centrally mediated disrup-
tion of ovarian function. Additional factors identified for
functional hypothalamic amenorrhea in humans include
intense physical exercise (32), anorexia/bulimia (33), and
weight loss (34). Biologic mechanisms linking these
various forms of stress, both physical and psychologic,
with functional hypothalamic amenorrhea may include
corticotrophin-releasing hormone (CRH) suppression of
gonadotropin-releasing hormone-producing neurons in the
central nervous system (35), resulting in impaired folliculo-
genesis in the ovary (36), although recent work by two of the
authors of the present study (S.L.B., K.A.M.) suggests that
CRH may not be the stimulus (36). The subgroup size of 20
women (21%) with functional hypothalamic amenorrhea in
our study unfortunately was too small to assess associations
with this entity alone, but using the larger subsample of 35%
women with hypoestrogenemia of hypothalamic origin, we
found no associations with body mass index, reported levels
of physical activity, weight cycling, anorexia/bulimia, or
recent acute illness. This lack of association may be due to
inadequate statistical power or may suggest that these
factors were not an operative cause of the hypoestrogenemia
of hypothalamic origin in the women in our study. Notably,
the mean age of women in our study (43 years) is older than
that in previous studies of functional hypothalamic amen-
orrhea (32–34), and we had very low prevalences of intense
exercise, low body weight, and anorexia/bulimia, suggesting
that the triggers of centrally disrupted ovarian function may
differ by age in women.
Although psychometric measures of environmental stress,
anxiety, and depression did not appear to be associated with
hypoestrogenemia of hypothalamic origin, this may have
been due to the relatively high levels of psychologic stress in
both groups of women in our study undergoing evaluation
for suspected myocardial ischemia, compounded by the
psychosocial assessment falling in close temporal proximity
to the coronary angiography. Our findings that the use of
anxiolytic/sedative/hypnotic medications and the absence of
Table 4. Significant Predictors of Hypoestrogenemia of
Hypothalamic Origin
Final Logistic Regression Model*
OR Conf. Intervals p
Anxiolytics, sedatives, or
hypnotics last week
4.6 1.3–15.7 0.02
Antidepressants last week 0.10 0.01–0.92 0.04
History of diabetes 3.4 1.1–10.2 0.03
c-Statistic  0.70
R2  0.19
*Without coronary artery disease, defined as70% luminal diameter stenosis inone
epicardial coronary artery, in the model. The variables of age, race, hypertension,
diabetes mellitus, body mass index, waist-hip ratio, current smoking, family history of
premature coronary artery disease, blood lipoprotein levels, Beck depression, environ-
mental stress, typical angina, and aspirin use were evaluated in the multivariate model.
OR  odds ratio.
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use of antidepressant medications were independent predic-
tors of hypoestrogenemia of hypothalamic origin suggest
biobehavioral links because these medications are prescribed
by physicians and may therefore more accurately reflect
ongoing clinical distress. The differing directions of associ-
ations between the two classes of medications (anxiolytic/
sedative/hypnotics vs. antidepressants) with hypothalamic
hypoestrogenemia might be interpreted as demonstrating
the difference between medications that treat symptoms
(anxiolytic/sedative/hypnotic) and those that beneficially
alter central nervous system function (antidepressants). Al-
ternatively, the negative association with antidepressant
drug use could signify untreated depression in women in our
study because there were no group differences in the
self-reported depression scores. Further work validating
these results and prospectively assessing social and psycho-
logic links is needed.
Not surprisingly, we did find a significantly higher
prevalence of diabetes mellitus among premenopausal
women with CAD in our study, but notably our results also
demonstrate a strong independent association between di-
abetes and hypoestrogenemia of hypothalamic origin. In-
deed, these findings are consistent with previous epidemi-
ologic data, which demonstrate that diabetic premenopausal
women have more frequent menstrual irregularities (37),
lower blood estrogen levels, and higher androgen levels than
non-diabetic women (38), factors that probably contribute
to the lower fertility rates observed in diabetic premeno-
pausal women. Menstrual irregularity is also predictive of
future diabetes (39) and may be a marker for polycystic
ovary syndrome (40), although the low levels of LH
observed in women in our study suggest that polycystic
ovary disease was not a contributor in this population. Our
finding of a diabetes-related estrogen deficiency, if validated
in prospective study, may provide an explanation for the
relatively greater coronary risk that diabetes conveys for
women than men, which has been observed repeatedly in
previous studies (41) and which remains unexplained.
Our multivariate analyses suggest that hypothalamic hy-
poestrogenemia is a significant predictor of CAD, consis-
tent with a previous report demonstrating an inverse rela-
tionship between estrogen levels and coronary artery severity
in premenopausal women (42) and with numerous animal
studies implicating estrogen as a key player in atherosclero-
sis (43,44). Notably, Kaplan and co-workers have demon-
strated that contraceptive hormone treatment inhibits the
acceleration of atherosclerosis observed in subordinate,
estrogen-deficient female monkeys (45). The use of hor-
mone replacement therapy with conjugated equine
estrogen-medroxyprogesterone acetate in older postmeno-
pausal women remains of uncertain value (10). Simple
replacement of estrogen may not fully address the underly-
ing hormonal abnormalities that are associated with hy-
poestrogenemia of hypothalamic origin.
Limitations. The current study results are limited by our
small sample size that reduces the confidence of our find-
ings. Specifically, calculations using a two-tailed alpha of
0.05 with 80% power indicate that group differences had to
be at least 37% to be detectable in the present sample. Also,
our cross-sectional design precludes inferring a causal rela-
tionship between hypothalamic hypoestrogenemia and an-
giographic CAD. Coronary artery disease may actually lead
to hypoestrogenemia of hypothalamic origin through un-
known pathophysiologic mechanisms, rather than resulting
as a consequence, as we have hypothesized. Alternatively, a
common explanatory mechanism, such as chronic stress,
could have an etiologic role in both disorders. Our measure
of environmental stress was a single question rather than a
scale and is probably less reliable and valid.
Conclusions. Among premenopausal women with coro-
nary risk factors undergoing coronary angiography for sus-
pected myocardial ischemia, hypoestrogenemia of hypotha-
lamic origin is associated with angiographic CAD. Use of
anxiolytic/sedative/hypnotic medication is an independent
predictor of hypoestrogenemia of hypothalamic origin in a
multivariate model, suggestive of a biobehavioral link.
These findings suggest the possibility that estrogen defi-
ciency due to central disruption of ovarian function may be
a risk factor for CAD in premenopausal women.
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